Psychiatric drug development still leans on rating scales developed decades ago: subjective instruments that capture how a patient describes feeling but not what the brain is doing. In major depressive disorder
(MDD), high patient variability, strong placebo responses and limited objective measures of treatment mechanisms can create challenges for trial design and go/no-go decisions. Electroencephalogram (EEG) and event-related potentials (ERP) offer objective, low-burden and inexpensive measures of brain function. This webinar explores where EEG and ERP can support MDD clinical trials, where they fit within a protocol and where their limitations should be considered.
The featured speakers will examine the published literature alongside their own research, including EEG signatures that can distinguish MDD patients from matched controls and track symptom severity. These signatures capture different aspects of the disorder, including cognitive function, emotional processing and behavioral attention. The panelists will discuss how these EEG signatures appear largely non-redundant, suggesting that different paradigms index different facets of the disorder and that a single "depression biomarker" may not capture this complexity. The panelists will also review evidence showing that targeted pharmacological intervention can shift these measures, positioning them as pharmacodynamic rather than exploratory tools.
The panel will focus on decisions development teams face when designing MDD clinical trials. Topics include whether EEG can improve pre-screening, inform dose selection and confirm target engagement earlier and more cost-effectively. The discussion will also address how anxiety, insomnia, disrupted sleep architecture and substance use disorders carry their own electrophysiological signatures and can confound a depression readout if left unmeasured.
The featured panelists will also discuss challenges related to reproducibility, standardization, effect sizes and the distance between group-level signal and individual patient prediction.
Register for this webinar to learn how EEG and ERP readouts can support patient stratification, dose selection and earlier treatment decisions in MDD clinical trials.
Who Should Attend
This webinar will appeal to:
Medical Directors, Clinical Program Leads and Development Heads running Phase I-III psychiatry programs and evaluating EEG endpoints
Translational Medicine and Biomarker Scientists responsible for selecting, qualifying and defending pharmacodynamic and target-engagement measures in CNS programs
Clinical Pharmacologists and Experimental Medicine teams working on dose selection, proof-of-mechanism and go/no-go criteria
Clinical Operations and Trial Design Specialists evaluating feasibility, endpoint strategy and vendor selection for multi-site studies
Biotech and Pharma Executives in neuroscience, psychiatry, psychedelic medicine, rapid-acting antidepressant development and addiction-adjacent programs
What You Will Learn
Attendees will gain insight into:
Which EEG and ERP measures have evidence behind them in MDD, including resting-state alpha power, N170 emotional bias, cognitive ERP components and P200 attention markers
Where EEG can add decision-making value in a trial protocol by informing dose selection, confirming central target engagement and providing early pharmacodynamic readouts before clinical efficacy emerges
How sleep EEG and comorbidity signatures, including insomnia, anxiety and substance use, can sharpen patient stratification and prevent confounded depression readouts
The limitations associated with reproducibility, standardization, realistic effect sizes and translating group-level signals into individual patient predictions
Register free on Xtalks:
https://xtalks.com/webinars/can-objective-brain-measures-improve-mdd-trial-decisions/
